# A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

> **NCT02912494** · PHASE3 · COMPLETED · sponsor: **Kissei Pharmaceutical Co., Ltd.**

## Conditions studied

- Anemia

## Interventions

- **DRUG:** JR-131
- **DRUG:** Darbepoetin alfa

## Key facts

- **NCT ID:** NCT02912494
- **Lead sponsor:** Kissei Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** — (—)
- **Last updated:** 2019-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02912494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02912494, "A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT02912494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*